Orgenesis Inc. and Kurve Therapeutics Inc. have announced promising preclinical study results for intranasal administration of a cell-based oncolytic virus-bearing product.
The mantra for a while has been that it's not good enough to get your drug approved, you've got to get it payed for, too. For gene therapy treatments, the payment is more complex, and you can add manufacturing and supply chain logistics to the list of challenges.
